Guggenheim Capital’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $468K | Sell |
49,921
-5,668
| -10% | -$53.2K | ﹤0.01% | 1217 |
|
|
2025
Q1 | $395K | Sell |
55,589
-4,000
| -7% | -$28.4K | ﹤0.01% | 1312 |
|
|
2024
Q4 | $695K | Sell |
59,589
-7,358
| -11% | -$85.8K | 0.01% | 1107 |
|
|
2024
Q3 | $1.38M | Buy |
66,947
+5,681
| +9% | +$117K | 0.01% | 962 |
|
|
2024
Q2 | $1.37M | Sell |
61,266
-2,229
| -4% | -$49.9K | 0.01% | 959 |
|
|
2024
Q1 | $1.75M | Buy |
63,495
+2,301
| +4% | +$63.3K | 0.01% | 934 |
|
|
2023
Q4 | $1.87M | Sell |
61,194
-10,486
| -15% | -$320K | 0.01% | 870 |
|
|
2023
Q3 | $2.27M | Sell |
71,680
-14,962
| -17% | -$473K | 0.02% | 765 |
|
|
2023
Q2 | $3.53M | Buy |
86,642
+3,874
| +5% | +$158K | 0.03% | 646 |
|
|
2023
Q1 | $3.08M | Sell |
82,768
-3,867
| -4% | -$144K | 0.03% | 696 |
|
|
2022
Q4 | $3.02M | Buy |
86,635
+14,977
| +21% | +$523K | 0.03% | 706 |
|
|
2022
Q3 | $4.01M | Sell |
71,658
-7,981
| -10% | -$447K | 0.04% | 584 |
|
|
2022
Q2 | $4.12M | Buy |
79,639
+3,320
| +4% | +$172K | 0.03% | 623 |
|
|
2022
Q1 | $5.55M | Buy |
76,319
+4,877
| +7% | +$354K | 0.03% | 610 |
|
|
2021
Q4 | $8.45M | Buy |
71,442
+14,563
| +26% | +$1.72M | 0.04% | 492 |
|
|
2021
Q3 | $7.63M | Buy |
56,879
+26,388
| +87% | +$3.54M | 0.05% | 486 |
|
|
2021
Q2 | $4.94M | Sell |
30,491
-617
| -2% | -$99.9K | 0.03% | 684 |
|
|
2021
Q1 | $2.5M | Buy |
+31,108
| New | +$2.5M | 0.02% | 917 |
|